Qiagen NV
Qiagen NV (QGEN) is an established provider of sample and assay technologies used in molecular diagnostics, life-science research and applied testing. The company's tools and kits help laboratories detect and analyse DNA, RNA and proteins — supporting areas such as infectious-disease testing, oncology, and personalised medicine. Revenue comes from recurring sales of consumables and instruments plus growing services tied to companion diagnostics and molecular tests. Geographic reach is global, exposing the business to developed and emerging market dynamics. Key catalysts include continued demand for molecular testing, expansion in oncology testing and the adoption of precision therapies. Investors should weigh these opportunities against risks: reimbursement pressure, regulatory scrutiny, competition from other diagnostics firms, foreign-exchange swings and possible volatility in instrument sales. With a market capitalisation near $10.5bn, Qiagen may suit investors seeking exposure to diagnostic technologies, but returns are not guaranteed. This is general information and not personal financial advice; consider your investment objectives and risk tolerance.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Qiagen's stock with a target price of $50.65, indicating growth potential.
Financial Health
Qiagen is performing well with strong profits and cash flow, indicating good business health.
Dividend
Qiagen's projected dividend yield of 0.03% is low, indicating limited returns for dividend-seeking investors. If you invested $1000 you would be paid $0.30 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring QGEN
Cell & Gene Therapy Logistics
This carefully curated collection features companies providing the essential infrastructure that makes advanced cell and gene therapies possible. Selected by expert analysts, these stocks represent the "picks and shovels" of the biotech revolution—giving you exposure to regenerative medicine's growth without the direct risks of clinical trials.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Recurring Consumables Revenue
Qiagen earns steady revenue from consumables and reagents that labs repurchase regularly, though sales can fluctuate with testing demand.
Global Diagnostics Reach
A broad international footprint gives exposure to varied markets and growth opportunities, but also brings foreign‑exchange and regional regulatory risks.
Oncology & Precision Medicine
Growth in companion diagnostics and personalised therapies could be a catalyst, while competition and reimbursement remain important considerations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
